Do Swedencare's (STO:SECARE) Earnings Warrant Your Attention?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Swedish (OMX) Pharma Industry Analysis
UpdatedJan 24, 2022
DataAggregated Company Financials
Companies43
- 7D-3.9%
- 3M-13.0%
- 1Y-8.9%
- YTD-15.6%
Over the last 7 days, the Pharma industry has dropped 3.9%, driven by a decline by Swedencare of 7.6%. Meanwhile, Infant Bacterial Therapeutics actually outperformed within the industry, gaining 12% in the last week. However, the industry is down 8.9% over the past year.
Industry Valuation and Performance
Has the Swedish Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Mon, 24 Jan 2022 | kr49.1b | kr5.5b | -kr1,083,939,448.00 | 112.1x |
| Wed, 22 Dec 2021 | kr55.2b | kr5.5b | -kr1,100,338,740.00 | 112.9x |
| Fri, 19 Nov 2021 | kr59.3b | kr5.3b | -kr1,355,585,770.00 | 88x |
| Sun, 17 Oct 2021 | kr52.9b | kr4.8b | -kr1,581,702,061.00 | 140.1x |
| Tue, 14 Sep 2021 | kr57.5b | kr4.8b | -kr1,560,489,765.26 | 153.5x |
| Thu, 12 Aug 2021 | kr55.4b | kr4.8b | -kr1,412,039,942.26 | 162.8x |
| Mon, 07 Jun 2021 | kr53.2b | kr4.6b | -kr1,469,283,209.50 | 173.3x |
| Sun, 28 Feb 2021 | kr51.4b | kr4.5b | -kr1,418,962,725.57 | 160.1x |
| Wed, 02 Dec 2020 | kr51.0b | kr4.4b | -kr913,043,309.17 | 81.6x |
| Sat, 05 Sep 2020 | kr45.6b | kr4.1b | -kr535,762,892.63 | 26x |
| Tue, 09 Jun 2020 | kr35.5b | kr3.7b | -kr414,746,201.62 | 28.4x |
| Mon, 02 Mar 2020 | kr28.3b | kr3.3b | -kr382,446,640.84 | 22.7x |
| Thu, 05 Dec 2019 | kr27.4b | kr3.0b | -kr628,422,177.00 | 40.6x |
| Sun, 08 Sep 2019 | kr25.2b | kr2.9b | -kr521,071,289.00 | 31.8x |
| Sat, 01 Jun 2019 | kr26.1b | kr3.3b | kr13.0m | 14.8x |
| Tue, 05 Mar 2019 | kr23.9b | kr2.6b | -kr83,038,134.00 | 15.2x |
PE Ratio
16.1x
Current Industry PE: Investors are more optimistic on the industry, considering it's trading at a PE ratio of 112x which is higher than its 3-year average PE of 73.5x. It appears they are confident that earnings will grow faster in the future than they have historically.
Past Earnings Growth: The earnings for companies in the Pharmaceuticals industry have deteriorated over the last three years, while revenues for these companies have grown 27% per year. This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Swedish Pharma industry?
| Pharma | -3.89% | |
Industry PE: Investors are most optimistic about the Pharma industry which is trading above its 3-year average PE ratio of 73.5x. This is likely because analysts are expecting annual earnings growth of 27%, which is higher than its past year's earnings decline of 26% per year.
Forecasted Growth: Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 27% over the next 5 years. This is better than its past earnings decline of 26% per year.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| IBT B Infant Bacterial Therapeutics | kr64.10 | 12.5% +kr79.7m | -51.1% | PB1.7x | |
| PILA PILA PHARMA | kr6.50 | 12.3% +kr11.4m | n/a | PB2.9x | |
| LIPUM Lipum | kr20.50 | 4.1% +kr4.0m | n/a | PB1.8x | |
| ODI ODI Pharma | kr5.10 | 1.2% +kr913.2k | -0.6% | PB5.1x | |
| FOLLI Follicum | kr0.35 | 2.9% +kr817.0k | -89.3% | PS61.2x |